Could an arthritis drug ease OCD? new study investigates
NCT ID NCT04786548
First seen Nov 05, 2025 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This study looks at whether the anti-inflammatory drug celecoxib (Celebrex) can help people with obsessive-compulsive disorder (OCD) who still have symptoms despite current medication. Researchers will use brain scans and blood tests to measure inflammation and see if it predicts who improves. The trial aims to enroll 21 adults aged 18 to 55 with OCD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New York State Psychiatric Institute
New York, New York, 10032, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
celecoxib (Celebrex)
What this could lead to
If successful, this could point toward a personalized treatment for OCD by identifying patients who benefit from anti-inflammatory medication.
What could go wrong
This is a small, early-phase trial with only 21 participants, and it is currently suspended. The drug may not reduce OCD symptoms, and results may not apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.